Titre:
  • Expression levels of ERBB2, ESR1, immune and proliferation signatures measured by RNASeq predict response to anti-HER2 treatment in the neoALTTO trial.
Auteur:Sotiriou, Christos; Venet, David; Fumagalli, Debora; Maetens, Marion M.; Rothé, Françoise; Ignatiadis, Michail; Bradbury, Ian; Harbeck, Nadia; Gomez, Henry; Chang, T; Coccia-Portugal, Maria; Di Cosimo, Serena; De Azambuja, Evandro; de la Peña, Lorena; Armour, A; Eidtmann, H.; Baselga, J; Piccart-Gebhart, Martine; Loi, Sherene
Informations sur la publication:Online, 18th ECCO - 40th ESMO European Cancer Congress(Vienna, Austria)
Statut de publication:Publié, 2015-09
Sujet CREF:Cancérologie
Médecine pathologie humaine
Sciences bio-médicales et agricoles
Note générale:Session Breast Cancer - Early Disease, Oral Presentation (abstract 1811)
Langue:Anglais